drugset / Trial / NCT03682744

CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC)

NCT03682744

Phase 1 Withdrawn Sorrento Therapeutics, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This is an open-label, dose-escalation, phase I trial of the safety and efficacy of anti-CEA intraperitoneal CAR-T infusions for treatment in patients with CEA-expressing adenocarcinoma peritoneal metastases or malignant ascites.

Timeline

Start
2018-09-13
Primary completion
2020-12
Completion
2021-03

Drugs

EvaluationDrugModalityDoseRoute
Subject anti-CEA CAR-T cells Cell therapy Other